Abbott Laboratories Corporation

Other

Abbott Laboratories D-337/ap6d

Joan D Tyner

Jeffrey C Hunt

Bailin Tu

James W Scheffel

Susan E Brophy

David J Hawksworth

Robert N Ziemann

Xiaoxing Qiu

John George Konrath

Sheng C Lou

Bryan C Tieman

Maciej B Adamczyk

Phillip G Mattingly

Donald D Johnson

Robert William Siegel

Mary M Perkowitz

Mary S Pinkus

Diana E Clarisse

Dinesh O Shah

Lowell J Tyner, Legal Representative

Suresh M Desai

Michael White

Saul A Datwyler

Frank C Grenier

Gregory Thomas Maine

Robin A Gutierrez

Ryan F Workman

Lawrence V Howard

Jessie W Shih

Sushil G Devare

Larry G Birkenmeyer

Jack S Remington

Qiaoqiao Ruan

Sergey Y Tetin

Jonathan P Belk

Dagang Huang

Sharmila Manoj

Dominick L Pucci

Linda E Chovan

Michael Jyh-Tsing Sheu

Susan Brojanac

Zhiguang Yu

Jeffrey M Werneke

Salman Ali

Hina N Syed

Larry T Mimms

Edward T Olejniczak

Carol S Ramsay

David J Daghfal

Matthew S Matias

Kevin R Rupprecht

Smriti U Mehta

Tracey D Rae

Jill E Johnson

Sheela M George

Mary S Gibadlo

Ryan M Bonn

Terry Y Nakagawa

David J Dagfal

Lianli Chi

Don C Laird

Don M Laird

Stephen F Parmley

Fausto Araujo

Yashuhiro Suzuki

David C Sogin

Shuli Li

John G Konrath

Bryan Tieman

James Scheffel

Gregory T Maine

Shuili Li

The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of

[object Object]

The subject invention relates to antibodies to troponin I as well as methods of use thereof. In particular, such antibodies may be used to detect Troponin I in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome.

Antibodies to troponin I and methods of use thereof

The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.

Monoclonal antibodies to human immunodeficiency virus and uses thereof

The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.

Antibodies that bind to mammalian NGAL and uses thereof

The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits.

PlGF-1 assay and kits and components thereof

Recombinant antibodies, including chimeric antibodies, specific for hepatitis C (HCV) antigenic proteins are provided. The recombinant antibodies specifically bind to diagnostically relevant regions of HCV proteins and are thus suitable for use, for example, as diagnostic reagents for the detection of HCV, and/or as standardization reagents or positive control reagents in assays for the detection of HCV. The recombinant antibodies can also be used in the treatment or prevention of a HCV infection.

Recombinant antibodies against hepatitis C virus and methods of obtaining and using same

A composition comprising neutrophil gelatinase-associated lipocalin (NGAL), which has been enriched from urine, has a molecular weight of about 24.9 kDa to about 25.9 kDa, and comprises a plurality of isoforms having isoelectric points (pIs) ranging from about 5.9 to about 9.1; a composition comprising NGAL, which has been enriched from recombinant Chinese hamster ovary (CHO) cells, has a molecular weight of about 25.9 kDa to about 27.9 kDa, and comprises a plurality of isoforms having pIs ranging from about 5.6 to about 9.1; a method of obtaining from urine a composition comprising a plurality of isoforms of NGAL, which method comprises enriching NGAL in urine without separating molecules based on charge; a method of obtaining from recombinant CHO cells a composition comprising a plurality of isoforms of NGAL, which method comprises enriching NGAL in a composition without separating molecules based on charge; and a method of analyzing NGAL isoforms enriched from urine or recombinant CHO cells comprising analyzing an enriched composition comprising NGAL isoforms by two-dimensional electrophoresis and Western blot.

Neutrophil gelatinase-associated lipocalin (NGAL) protein isoforms enriched from urine and recombinant chinese hamster ovary (CHO) cells and related compositions, antibodies, and methods of enrichment, analysis and use

An isolated antibody that specifically binds to sFlt-1 or a fragment thereof having (i) a variable heavy domain region comprising the amino acid sequence of SEQ ID NO: 2, (ii) a variable light domain region comprising the amino acid sequence of SEQ ID NO: 4, or (iii) both (i) and (ii), a pharmaceutical composition and a kit comprising such an antibody, a method of making such an antibody, a method of determining the presence, amount or concentration of sFlt-1 or a fragment thereof in a test sample, a method of treating a patient in therapeutic or prophylactic need of an antagonist of sFlt-1, an isolated nucleic acid comprising a nucleotide sequence encoding the amino acid sequence of (i) SEQ ID NO: 2, (ii) SEQ ID NO: 4, or (iii) both (i) and (ii), optionally as part of a vector, and a host cell comprising and expressing such a nucleic acid.

Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making

The present invention relates among other things to antibodies that immunospecifically bind to at least one agent of interest (e.g., an immunosuppressive agent), methods for producing such antibodies, and immunoassays that employ said antibodies. Additionally, the present invention also relates to methods for selecting an antibody for use in a diagnostic immunoassay and methods for selecting an antigen for use in a diagnostic immunoassay. The present invention further relates to the improvement of antibody recognition of an active parent drug in the presence of one or more of its major metabolites.

Immunosuppressant binding antibodies and methods of obtaining and using same

The present invention relates to antibodies that immunospecifically bind to human brain natriuretic peptide or a human brain natriuretic peptide fragment with a high binding affinity, methods for producing and selecting said antibodies, immunoassays for human brain natriuretic peptide or a human brain natriuretic peptide fragment that employ said antibodies and therapeutic compositions containing said antibodies.

Human BNP immunospecific antibodies

Methods for the detection of HIV-1 or -2 antigens employing monoclonal antibodies that recognize a shared HIV-1/-2 epitope in the capsid p24/p26 proteins

Growing community of inventors

Beach Park, IL, United States of America

Joan D Tyner